Given the widespread presence of CDK4‐amplification/high expression and CDKN2A loss across sarcomas subtypes, CDK4 inhibitors such as palbociclib are also a promising strategy in RB‐positive tumors (Dickson et al, 2013). Here, CDKN2A is linked to sarcoma.